CALIXAR team will be present at the online Bio Japan event, from October 13 to 15, 2021 to discuss about commercial and scientific opportunities linked to our activities.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.
About Bio Japan:
This event is constituted by three exhibitions – The world’s oldest biotechnology exhibition “BioJapan” (1986), “Regenerative Medicine JAPAN” (2016), aiming at accelerating and industrializing R&D in the field of regenerative medicine including iPS cells, and “health TECH JAPAN”(2020), provides fusion of digital technology and life science.
The goal is to provide new value through business partnering of industry, academia, and government which is not limited to Japan, but also from overseas. With the addition of Digital & In-Person partnering program started from 2020, global innovation through this partnering event never stops at all.